|
|
| (5 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {| class="infobox" style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width: 250px;" cellpadding="0" cellspacing="0"; | | |
| ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF;" align=center | [[Metoprolol|{{fontcolor|#2B3B44|Metoprolol}}]]
| | {{cquote| quote here |
| |- | | }} |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | [[Lopressor|{{fontcolor|#2B3B44|Lopressor (metoprolol tartrate) tablet}}]]
| | |
| |- | | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor indications and usage|Indications and Usage]]
| | |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor dosage and administration|Dosage and Administration]]
| | |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor dosage forms and strengths|Dosage Forms and Strengths]]
| | |
| |- | | {{Family tree/start}} |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor contraindications|Contraindications]] | | {{Family tree|border=0|boxstyle=background: #FF0000; color: #F8F8FF;| | | | | | | | | | | | | A01 | | | | | | | | | | | | | |A01= |
| |- | | <div style="text-align: left; height: 150px; width: 200px; padding: 5px;"> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor warnings and precautions|Warnings and Precautions]]
| | '''Symptoms & Signs''' <BR> |
| |- | | ---- |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor adverse reactions|Adverse Reactions]]
| | ❑ Altered mental status <BR> |
| |- | | ❑ Cyanosis <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor drug interactions|Drug Interactions]]
| | ❑ Hypotension (MAP <60 mmHg)<BR> |
| |- | | ❑ Oliguria (<0.5 mL/kg/h) <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor use in specific populations|Use in Specific Populations]]
| | ❑ Tachycardia <BR> |
| |- | | ❑ Tachypnea |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor overdosage|Overdosage]]
| | </div>}} |
| |- | | {{Family tree|border=0|boxstyle=background: #FF0000; color: #F8F8FF;| | | | | | | | | | | | | |!| | | | | | | | | | | | | | |}} |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor description|Description]]
| | {{Family tree|border=0|boxstyle=background: #FF0000; color: #F8F8FF;| | | | | | | | | | | | | B01 | | | | | | | | | | | | | |B01= |
| |- | | <div style="text-align: center; height: 25px; width: 200px;"> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor clinical pharmacology|Clinical Pharmacology]]
| | '''Shock''' |
| |- | | </div>}} |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor nonclinical toxicology|Nonclinical Toxicology]]
| | {{Family tree|border=0|boxstyle=background: #FF0000; color: #F8F8FF;| | | | | | | | | | | | | |!| | | | | | | | | | | | | | |}} |
| |- | | {{Family tree|border=0|boxstyle=background: #FF0000; color: #F8F8FF;| | | | | | | | | | | | | C01 | | | | | | | | | | | | | |C01= |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor clinical studies|Clinical Studies]]
| | <div style="text-align: left; height: 520px; width: 200px; padding: 5px;"> |
| |- | | '''Resuscitation''' <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor how supplied storage and handling|How Supplied/Storage and Handling]]
| | ---- |
| |- | | ❑ 0.5—1 L every 10—15 minutes<sup>†</sup> <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor patient counseling information|Patient Counseling Information]]
| | ❑ ± Morphine 2—4 mg boluses <BR> |
| |- | | ❑ Ventilatory support <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor labels and packages|Labels and Packages]] | | '''Labs & Imaging''' <BR> |
| |- | | ---- |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor pill images|Pill Images]]
| | ❑ CBC/DC/SMA-7/PT/PTT <BR> |
| |- | | ❑ Arterial blood gas <BR> |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | [[Toprol XL|{{fontcolor|#2B3B44|Toprol XL (metoprolol succinate) tablet, extended release}}]]
| | ❑ Lactate <BR> |
| |- | | ❑ ECG <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL indications and usage|Indications and Usage]]
| | ❑ CXR <BR> |
| |- | | ❑ Echocardiography <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL dosage and administration|Dosage and Administration]]
| | ❑ CXR <BR> |
| |- | | ❑ Central venous catheter <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL dosage forms and strengths|Dosage Forms and Strengths]]
| | ❑ Pulmonary artery catheter <BR> |
| |- | | '''Immediate Goals''' <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL contraindications|Contraindications]]
| | ---- |
| |- | | ❑ MAP >60—65 mmHg <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL warnings and precautions|Warnings and Precautions]]
| | ❑ CVP 8—12 mmHg <BR> |
| |- | | ❑ PCWP 12—15 mmHg <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL adverse reactions|Adverse Reactions]]
| | ❑ CI >2.1 L/min/m<sup>2</sup> <BR> |
| |- | | ❑ Hemoglobin >7—9 g/dL <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL drug interactions|Drug Interactions]]
| | ❑ SaO2 >90%—92% <BR> |
| |- | | ❑ MVO2 >60% <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL use in specific populations|Use in Specific Populations]]
| | ❑ SCVO2 >70% <BR> |
| |- | | ❑ Lactate <2.2 mM/L <BR> |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL overdosage|Overdosage]]
| | ❑ Urine output >0.5 mL/kg/h |
| |-
| | </div>}} |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL description|Description]]
| | {{Family tree|border=0|boxstyle=background: #FF0000; color: #F8F8FF;| | | | | | | | | | | | | |!| | | | | | | | | | | | | | |}} |
| |-
| | {{Family tree|border=0|boxstyle=background: #FF0000; color: #F8F8FF;| | | | | | | | | | | | | D01 | | | | | | | | | | | | | |D01= |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL clinical pharmacology|Clinical Pharmacology]]
| | <div style="text-align: left; height: 130px; width: 200px;"> |
| |-
| | </div>}} |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL nonclinical toxicology|Nonclinical Toxicology]]
| | {{Family tree/end}} |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL clinical studies|Clinical Studies]]
| | <sup>†</sup> 100—200 mL boluses for cardiogenic shock |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL how supplied storage and handling|How Supplied/Storage and Handling]]
| | |
| |- | | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL patient counseling information|Patient Counseling Information]]
| | |
| |- | | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL labels and packages|Labels and Packages]] | | |
| |- | | ---- |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL pill images|Pill Images]]
| | |
| |- | | |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | [[Metoprolol (patient information)|{{fontcolor|#2B3B44|Patient Information}}]]
| | |
| |-
| | |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | [http://clinicaltrials.gov/search/open/condition=Metoprolol {{fontcolor|#2B3B44|Clinical Trials}}]
| | <div style="width: 1px; height: 1px; background-color: #999999; position: fixed; top: 10px; left: 10px"> |
| |-
| | |
| |}
| | </div> |